Perspective Therapeutics presents at World Molecular Imaging Congress

Perspective Therapeutics announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress, WMIC, 2024, held on September 9-13, 2024, in Quebec, Canada. Presentation One: Preclinical evaluation of Pb-PSV-359: The objective of this study is to evaluate Pb-radiolabeled PSV-359 in vitro and in vivo. PSV359 comprises a novel cyclic peptide targeting human FAP, and a molecular linker to a lead-specific chelator. The researcher found that in vitro, Pb-PSV-359 demonstrated superior FAP binding affinity and specificity, and that Pb-PSV-359 showed strong tumor uptake and clearance from the blood via the renal system. Presentation Two: Customizing chelators for targeted radionuclide therapy: Insights from computational modeling: Researchers demonstrated the use and importance of computational methods to guide customization of chelators